Cointime

Turning Point Therapeutics

company

About

Turning Point Therapeutics is a pharmaceutical company that discovers and develops precision medicines for cancer and other diseases.

  • 251 - 500

Highlights

Total Funding Amount
$125M
Funding Rounds
2
Investors
1

Details

Last Funding Type
Private Equity（PE）
Last Funding Money Raised
$80M
Industries
Biotechnology,Health Care,Pharmaceutical,Therapeutics
Founded date
Oct 8, 2013
Number Of Employee
251 - 500
Operating Status
Active

Turning Point Therapeutics is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. They focus on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating the tumor microenvironment and tumor immunity.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$125M
Turning Point Therapeutics has raised a total of $125M in funding over 2 rounds. Their latest funding was raised on Oct 19, 2018 from a Private Equity（PE） round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 19, 2018 Private Equity（PE） $80M 1 — — Detail
May 23, 2017 Series C $45M 1 Lilly Asia Ventures — Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Turning Point Therapeutics is funded by 1 investors. Lilly Asia Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Lilly Asia Ventures — Private Equity（PE）
Cointime
เนื้อหา
บริษัท